Beyond Meat Trims Q3 Net Revenues Outlook - Quick Facts

Beyond Meat, Inc. (BYND) announced Friday that it is reducing its third quarter net revenues outlook, now projecting net revenues of about $106 million, compared to the prior guidance range of $120 million to $140 million.

On average, 13 analysts polled by Thomson Reuters expect the company to report net revenues of $133.11 million for the quarter.

Although the company's previous third quarter guidance anticipated a sequential decline in net revenues, the deceleration was larger than anticipated.

The company believes demand was impacted by broader ongoing macro and micro-economic factors, including among others, the effects of the COVID-19 Delta variant.

The Company also experienced a decrease in retail orders that persisted longer than expected from a Canadian distributor coinciding with the reopening of restaurants, driven by the effects of the COVID-19 Delta variant. Further, it experienced challenges in operations that led to unfulfilled orders, with severe weather as a key driver.

These impacts were partially offset by accelerated orders from an international customer during the third quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated.. Covid vaccine maker Moderna Inc.'s Chief Executive Stéphane Bancel has predicted that existing COVID-19 vaccines will be much less effective against Omicron than earlier strains, according to the Financial Times.
Follow RTT